Tags : Human Clinical Trials


Evotec and Exscientia Initiate Human Clinical Trials of their Novel

Shots: The companies initiate the clinical trial of A2a receptor antagonist, co-developed by Exscientia and Evotec utilizing Exscientia’s AI-design platform, Centaur Chemist Exscientia will lead the clinical development phase of the molecule and Evotec retains co-ownership rights throughout clinical development The A2a receptor is currently in development for adult patients with advanced solid tumors and […]Read More